BCR-ABL is a gene produced by the fusion of the bcr gene and the c-abl proto-oncogene and is considered to be the main cause of chronic myelogenous leukemia (CML) production. Therefore, the development of selective Bcr-Abl kinase inhibitors is an attractive strategy for the treatment of CML.
Xcess Biosciences Inc (XcessBio or Xbio) was founded in 2008 by scientists from academia and BioPharma industry with strong expertise in chemistry and biology. We are dedicated to develop high-quality products and deliver the best services for our customers.
Your orders will be processed within 24 hours if the requested items are available in stock. We do not ship out orders on Friday. Orders received on Friday will be shipped out in the morning of the following Monday.
We diligently develop high quality products and strive to earn your satisfaction. If for any reason you are not satisfied with your purchases, please follow our Return Policy for product return or exchange.
If you know of any technology, product, or service development opportunities in the fields related, we would be very interested in hearing from you. Please Contact Us.